Medifast Reports $72 Million in Q3 Revenue and $17.5 Million Net Loss

What happened

Medifast reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, and a net loss of $17.5 million. It expects fourth-quarter revenue of $55 million to $75 million and adjusted EBITDA, which means earnings before interest, taxes, depreciation and amortization, of $2 million to $6 million.

Confirmed

Global impact / market context

The company's sales force is shrinking fast, with active earning coaches down 47.7% to 10,200, so fewer people are selling its products. Management links this to clients choosing GLP-1 weight-loss medicines instead, which pressures future revenue and makes the planned fourth-quarter recovery uncertain.

Analyst inference

Revenue per active coach rose 54.1%, meaning the remaining sellers generate more sales each, but that did not offset the smaller network. The wider operating loss of $19.4 million shows costs did not fall as fast as revenue, so cash generation and the fourth-quarter guidance range are the key tests.

Analyst inference

What to watch

1. Medifast expects coach numbers to keep declining through year-end, so watch whether the fourth-quarter revenue result lands inside the guided $55 million to $75 million range despite fewer sellers. Confirmed
2. Watch whether management acts to stabilize the independent coach network, since a smaller sales force reduces the pool of people selling products and could keep pressuring revenue into next year. Proposed
3. Watch the gap between the $19.4 million operating loss and revenue, because if costs stay high while sales fall, cash available could tighten and force changes to spending plans. Analyst inference

Evidence

• Original source link unavailable